BURNABY, British Columbia / Apr 01, 2025 / Business Wire / As of today, the Government of Saskatchewan’s expanded public coverage for continuous glucose monitoring (CGM) systems comes into effect. Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds this decision as a testament to the government’s commitment to improving diabetes care. The expansion, which now provides full coverage for continuous glucose monitoring systems for young adults ages 18 to 25 and seniors ages 65 and over, marks a significant step toward improving clinical outcomes and enhancing the quality of life for nearly 10,000 individuals living with diabetes in the province.
As part of the provincial government’s recent Budget 2025 announcement, Dexcom G7 and Dexcom G6 CGM systems are now publicly covered for residents living with diabetes age 18-25 and those over 65 who use any type of insulin, in addition to the previously reimbursed group of people ages 2-18.
Canadians who rely on insulin are at risk of experiencing severe hypoglycemia, which can cause complications and potentially be fatal. Select continuous glucose monitoring systems, such as Dexcom G7 and Dexcom G6, are equipped with a predictive Urgent Low Soon alert that can warn users up to 20 minutes in advance of a severe hypoglycemic event (< 3.1 mmol/L), prompting the user to take preventative action. This exclusive feature of Dexcom CGM systems can mean the difference between experiencing hypoglycemia or potentially avoiding it altogether.
"Managing diabetes presents unique challenges for Canadians who rely on insulin. While insulin is life-sustaining, determining the appropriate dosage can be challenging without the data provided by continuous glucose monitoring systems," says André Côté, Vice-President and General Manager, Dexcom Canada. "The Government of Saskatchewan’s decision to provide public coverage for Dexcom CGM, regardless of insulin type, is a significant and positive step forward for the diabetes community. This initiative will allow more Saskatchewan residents to benefit from Dexcom CGM, offering them real-time insights for more informed decision-making and effective diabetes management."
Dexcom CGM users also have access to a variety of connected health solutions, including several insulin pumps to automate insulin delivery and digital health apps to personalize care and provide a more holistic view of diabetes management.
Other Dexcom apps, such as the Dexcom Follow app†, allow family members and loved ones to remotely monitor the user’s glucose levels, providing additional security and peace of mind for those who may need it most.
To learn more about Dexcom CGM and public and private coverage options available, please visit dexcom.com.
About Dexcom, Inc.
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.
*For a list of compatible devices, visit dexcom.com/compatibility.
† Following requires the Dexcom Follow app and an Internet connection. Followers should always confirm readings on the Dexcom G6 or G7 apps before making treatment decisions. For a list of compatible devices, visit dexcom.com/compatibility.
Last Trade: | US$68.14 |
Daily Change: | 0.82 1.22 |
Daily Volume: | 2,466,868 |
Market Cap: | US$26.620B |
March 25, 2025 March 10, 2025 February 27, 2025 January 13, 2025 December 17, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load